MEK inhibitor (MEK-I) administration would inhibit the reactivation of the MAPK pathway induced by BRAF-I resistance and, as a result, would restore IFNAR1 expression on melanoma cells when it is downregulated by ERK reactivation [22]. This evidence concerns the gene MAP2K7 and melanoma.